logo
ENTITY
Daiichi Sankyo

Daiichi Sankyo (4568 JP)

140
Analysis
Health Care • Japan
Daiichi Sankyo Co, Ltd is a holding company established through merger of Sankyo and Daiichi pharmaceutical. The Group manufactures pharmaceuticals for human/veterinary use and medical tools and equipment. It also researches and promotes products through related companies throughout the world. The Group also produces food, food additives, livestock feeds, and agrochemicals.
more
bullish•Daiichi Sankyo
•07 May 2018 18:39

Domestic Business Driven FY17 Topline Growth Is Not Sustainable

Daiichi Sankyo Co Ltd (4568 JP)'s FY17 results Domestic pharma performance (up ~7% y-o-y to ¥613b and contribution up 400bps to 64% of total sales...

Logo
Share
bullish•Thematic (Sector/Industry)
•24 Apr 2018 22:17

Japan Pharma - FY17e Earnings Preview (I)

Astellas Pharma Inc (4503 JP) - April 26, 2018FY18e potential guidance  Moderate Xtandi and Tarceva growth and Vesicare US patent expiry led y-o-y...

Logo
Share
bullish•Takeda Pharmaceutical
•29 Mar 2018 14:03

Japan Pharmaceutical - Sector Overview

Core coverage – relative valuations Takeda Pharmaceutical Co Ltd (4502 JP) (NB: Pre-Shire announcement | Pro-Forma analysis to be published...

Logo
Share
bearish•Fast Retailing
•12 Feb 2018 08:14

Trading the BOJ-Nikkei 225 Baskets

One week ago in The BOJ's Ongoing ETF Impact - Is a Nikkei 225 Reshuffle in the Cards? I discussed the BOJ's past and current ETF purchasing...

Logo
Travis Lundy
469 Views
Share
bearish•Fast Retailing
•04 Feb 2018 14:29

The BOJ's Ongoing ETF Impact - Is a Nikkei 225 Reshuffle in the Cards?

Just over six months ago, a breathless article on Bloomberg noted that according to their calculations, the BOJ owned 71% of the ETFs in the...

Logo
Travis Lundy
1.6k Views
Share

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.40.5

x